Scholar Rock Files 8-K
Ticker: SRRK · Form: 8-K · Filed: Sep 23, 2025 · CIK: 1727196
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: SRRK
TL;DR
SRRK filed an 8-K on 9/23/25 covering Reg FD, other events, and financials.
AI Summary
Scholar Rock Holding Corp. filed an 8-K on September 23, 2025, reporting on events including Regulation FD disclosures, other events, and financial statements. The company, incorporated in Delaware, is based in Cambridge, MA, and operates in the biological products sector.
Why It Matters
This filing provides an official record of significant corporate events and disclosures for Scholar Rock Holding Corp., which could impact investors and stakeholders.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on corporate events and does not inherently signal high risk.
Key Numbers
- 001-38501 — Commission File Number (SEC File Number for Scholar Rock)
- 82-3750435 — EIN (IRS Employer Identification Number)
Key Players & Entities
- Scholar Rock Holding Corp. (company) — Registrant
- September 23, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Cambridge, MA (location) — Principal Executive Offices
- 301 Binney Street, 3rd Floor (address) — Principal Executive Offices Address
FAQ
What specific events are detailed in the Regulation FD Disclosure section?
The filing indicates a Regulation FD Disclosure but does not specify the exact content within this 8-K excerpt.
Are there any material financial updates provided in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, suggesting financial information is included, but the details are not present in this excerpt.
What is the primary business of Scholar Rock Holding Corp.?
Scholar Rock Holding Corp. operates in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' sector, classified under SIC code 2836.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 23, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 301 Binney Street, 3rd Floor, Cambridge, MA 02142.
Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-09-23 07:04:58
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share SRRK The Nasdaq Global Sel
Filing Documents
- tm2526733d1_8k.htm (8-K) — 23KB
- tm2526733d1_ex99-1.htm (EX-99.1) — 17KB
- 0001104659-25-092317.txt ( ) — 208KB
- srrk-20250923.xsd (EX-101.SCH) — 3KB
- srrk-20250923_lab.xml (EX-101.LAB) — 33KB
- srrk-20250923_pre.xml (EX-101.PRE) — 22KB
- tm2526733d1_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On September 23, 2025, Scholar Rock Holding Corporation (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter ("CRL") regarding the Biologics License Application ("BLA") for apitegromab for the treatment of spinal muscular atrophy ("SMA"). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On September 23, 2025, the Company announced that the FDA has issued a CRL regarding the BLA for apitegromab for the treatment of SMA.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by the Company on September 23, 2025, furnished hereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Scholar Rock Holding Corporation Date: September 23, 2025 By: /s/ Junlin Ho Junlin Ho General Counsel & Corporate Secretary